ALT – altimmune, inc. (US:NASDAQ)

News

Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
Altimmune to Participate at Two Upcoming Conferences
Altimmune, Inc. (NASDAQ: ALT) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
Altimmune Statement on the Passing of Dr. Stephen Harrison
Global COVID-19 Testing Strategic Analysis Report 2024: Market to Reach $5.8 Billion by 2030 from $19.9 Billion in 2023 [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com